Century Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 27, 2023, covers the results of Century Therapeutics, Inc.'s 2023 Annual Meeting of Stockholders. The meeting was conducted virtually. As of the record date of April 28, 2023, there were 59,580,817 outstanding shares of common stock.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal 1: Election of Class II Directors
- Cynthia Butitta: Elected with 50,643,653 votes For, 808,082 Withheld, and 3,952,285 Broker Non-Votes.
- Timothy Walbert: Elected with 47,566,726 votes For, 3,885,009 Withheld, and 3,952,285 Broker Non-Votes.
- Alessandro Riva, M.D.: Elected with 50,658,311 votes For, 793,424 Withheld, and 3,952,285 Broker Non-Votes.
- Proposal 2: Ratification of Independent Registered Public Accountants
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2023 fiscal year.
- Votes For: 55,396,113
- Votes Against: 5,068
- Abstentions: 2,839
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Cynthia Butitta, Timothy Walbert, and Alessandro Riva, M.D.) through the 2026 Annual Meeting.
- Confirm the appointment of Ernst & Young LLP as the auditor for the 2023 fiscal year.
- Note the significant number of broker non-votes (3,952,285) on the director election proposals.
- Review the definitive proxy statement filed on April 28, 2023, for detailed descriptions of the proposals.